Pharsight Licenses Diabetes Meta-Database to Undisclosed Biotech | GenomeWeb
NEW YORK (GenomeWeb News) — Pharsight has licensed its public-source type II diabetes meta-database to an undisclosed biotechnology company, the informatics shop said today.
The deal is the firs time Pharsight has licensed one of its 20 meta-databases, which compare the “simulated” efficacy and safety of candidate drugs against those of existing drugs, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.